Faculty: Hannah M. Lee, MD Geneve Allison, MD
|
|
- Godfrey Ferguson
- 5 years ago
- Views:
Transcription
1 pmicme Updates April 11, 2012 Anaheim, California Faculty: Hannah M. Lee, MD Geneve Allison, MD
2 Session 3: SCALE HBV: Screening, Counseling and Linkage to Care Education Learning Objectives 1. Apply the guidelines for hepatitis B virus (HBV) screening in appropriate at-risk populations. 2. Develop tactics to overcome patient objections to HBV screening, treatment, and/or vaccination. 3. Demonstrate how to correctly interpret screening/diagnostic results. 4. Appropriately manage HBV patients with respect to treatment, monitoring, and/or referral. Faculty Hannah M. Lee, MD Assistant Professor of Medicine Division of Gastroenterology and Hepatology Director, Asian-Pacific Liver Wellness Tufts University School of Medicine Boston, Massachusetts Dr Hannah Lee is assistant professor of medicine in the Division of Gastroenterology/Hepatology and director of the Asian- Pacific Liver Wellness Program at Tufts Medical Center Tufts University School of Medicine, located in the heart of Boston s Chinatown. Dr Lee specializes in general hepatology and transplant hepatology, and has a particular interest in viral hepatitis. Her research is currently focused on best practices among primary care physicians in hepatitis B screening in the Boston area and improving screening rates within the city s Asian community. Dr Lee is actively involved in addressing Asian health disparities, particularly in the area of hepatitis B, both at the local and national levels. She is a board committee member of the Asian Health Initiative at Tufts Medical Center and serves on the advisory board of the Asian Health Foundation. Both in her clinical practice and in her involvement in community health, Dr Lee has been a strong advocate in addressing practice and knowledge gaps in HBV screening, counseling, and linkage to care. Geneve Allison, MD, FACP Assistant Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts University School of Medicine Boston, Massachusetts Dr Geneve Allison is an assistant professor of medicine at Tufts University School of Medicine and an attending physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center in Boston. Dr Allison graduated cum laude from Harvard College in Cambridge, Massachusetts, in 1993 with an AB in biology, and received her MD from University of Massachusetts Medical School in Worcester in She was an intern, resident, and chief resident at the Alameda County Medical Center in Oakland, California, from 2000 to 2004, and was Resident of the Year. Dr Allison joined Tufts Medical Center as an infectious diseases fellow in During her T32 National Institutes of Health (NIH) funded research years, she studied humoral immunity to Cryptosporidium in Bangladeshi children with diarrhea. In 2005, she was awarded the Tufts Gorbach prize for best clinical/translational research by an infectious diseases fellow. Two years later, Dr Allison became an infectious diseases attending at Tufts. From 2007 to 2011, Dr Allison served as assistant, then associate, director of the Infectious Diseases Fellowship Program at Tufts. In July 2011, she began a two-year NIH-funded career development grant through the Tufts Clinical and Translational Science Institute (CTSI) focusing on Outpatient Parenteral Antibiotic Therapy (OPAT) outcomes. Dr Allison s clinical interests include patient safety and care coordination stemming from her role as OPAT director. Session 3
3 Faculty Financial Disclosure Statements The presenting faculty report the following: Dr Lee reports that she has received honoraria from Gilead Sciences Medical Affairs. Dr Allison has no financial relationships to disclose. Education Partner Financial Disclosure Statement The following content collaborators at DKBmed, LLC, report the following: Josh Kilbridge;., Crystal Johnson; Pat Galinski, EdD; Stan Pogroszewski, JD; and Dean Beals have no financial relationships to disclose. Suggested Reading List American Association for the Study of Liver Diseases. HBV Specialty-Based Slide Sets. Accessed March 21, Chang MH. Natural history of hepatitis b virus infection in children. J Gastroenterol Hepatol. 2000;15 Suppl:E16-E19. Chen CJ, Yang HI, Su J, et al.; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1): Leung N. Chronic hepatitis B in Asian women of childbearing age. Hepatol Int. 2009;3(Suppl 1): McCracken M, Olsen M, Chen MS Jr, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 2007;57(4): Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28: Stanford School of Medicine Asian Liver Center. FAQs about Hepatitis B. Accessed March 21, Weinbaum CM, William I, Mast EE, et al.; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1-20. World Health Organization. Department.. of Communicable Diseases Surveillance and Response. Hepatitis B. WHO/CDS/LYO/2002.2:Hepatitis B. Accessed March 21, Session 3
4 PROGRAM GOAL Geneve Allison, MD, FACP Assistant Professor of Medicine Division of Geographic Medicine Tufts University School of Medicine Boston, MA The goal of this activity is to address key practice and knowledge gaps in hepatitis type B screening, counseling, and linkage to care, and adherence to clinical guidelines when treating Asian, Asian-American, and African immigrant patients. EDUCATIONAL OBJECTIVES Apply the guidelines for hepatitis B virus (HBV) screening in appropriate at-risk populations Develop tactics to overcome patient objections to HBV screening, treatment, and/or vaccination Demonstrate how to correctly interpret screening/diagnostic results Explain the need to properly treat, monitor, or refer their HBV patients PRE SEMINAR QUESTIONS How many Asian/Asian-American patients do you see each week How many African immigrant patients do you see each week 1. < >20 1. < >20 1
5 Please rate your confidence in correctly identifying a patient s risk for chronic HBV. Please rate your confidence in treating patients for chronic HBV. 1. Not Confident 2. Somewhat Confident 3. Neutral 4. Confident 5. Very Confident 1. Not Confident 2. Somewhat Confident 3. Neutral 4. Confident 5. Very Confident PATIENTS IN WHICH OF THE FOUR PHASES OF HBV LIFECYCLE SHOULD BE TARGETED FOR TREATMENT How often do you screen Asian/Asian American patients for chronic HBV 1. Immune tolerant 2. Immune active/clearance phase 3. Inactive carrier 4. Precore mutant with normal ALT 1. Rarely 2. Sometimes 3. Often 4. Always How often do you screen African immigrant patients for chronic HBV 1. Rarely 2. Sometimes 3. Often 4. Always Please rate your confidence in your ability to interpret hepatitis B screening test results correctly. 1. Not Confident 2. Somewhat Confident 3. Neutral 4. Confident 5. Very Confident 2
6 GEOGRAPHIC DISTRIBUTION OF CHRONIC HBV INFECTION EPIDEMIOLOGY AND RISKS OF UNTREATED HBV Hannah Lee, MD Assistant Processor of Medicine Division of Gastroenterology & Hepatology Director, Asian-Pacific Liver Wellness Program Tufts Medical Center Boston, MA HBsAg Prevalence* 8% (high) 2% to 7% (intermediate) < 2% (low) Weinbaum CM, et al. MMWR Recomm Rep. 2008;57(RR-8):1-20. *HBsAg, Hepatitis B surface antigen IMMIGRATION HAS A HIGH IMPACT ON US HBV PREVALENCE Immigration Numbers by Continent: ~ 3.6 million Asians 50 MILLION HBV INFECTED IN AFRICA Worldwide, one in seven persons with Chronic Hepatitis B lives in Africa. In some African countries, prevalence of marker of past exposure or infection to HBV as high as 98% 1 HBsAg Prevalence 2 8% (high) 2% to 7% (intermediate) < 2% (low) ~ 1.3 million Europeans ~ 875,000 South Americans 1. US Department of Homeland Security. Yearbook of Immigration Statistics: Weinbaum CM, et al. MMWR Recomm Rep. 2008;57(RR-8):1-20. ~ 804,000 Africans Rates of HBSag carrier range from 9% in South Africa to 20% in Democratic Republic of Congo. 2 Estimated 12.5 million deaths will occur in this population because of HBV (230,000 deaths per year) 2 Acute viral hepatitis, chronic hepatitis, cirrhosis and HCC responsible for at least 12% of hospital admissions, and over 20% of hospital mortality in many parts of Africa. 3 1 Kiire et al Gut 1996; 38 (suppl2):s5-s and-hiv-in-africa-being-ignored/page/ Eldryd et al. AIDS. In: Principles of Medicine in Africa. 3rd ed. Cambridge 2004; PREVALENCE OF HBV AMONG ASIAN AMERICANS POTENTIAL CONSEQUENCES OF CHRONIC HBV Survey of screening programs in 5 large US cities ( ) Chinese Korean Vietnamese Median age: 43 (12-80) HBsAg positive: 558/5341 (10.4%) 0% 2% 4% 6% 8% 10% 12% 14% 16% Philadelphia San Francisco Boston Chicago NY(1) NY(2) 11% 14% 10% 11% 15% 11% Cirrhosis End-stage Liver Disease Hepatocellular Carcinoma (HCC) HBV causes 60-80% of liver cancer cases worldwide. HBV is a carcinogen that is second only to smoking tobacco in causing cancer deaths worldwide. Overall 10.4% Guan R, et al. AASLD Abstract
7 HEPATITIS B DISEASE PROGRESSION Liver Cancer (HCC) HBV DNA ASSOCIATED WITH INCREASED RISK OF HCC AND CIRRHOSIS REVEAL: Prospective Observational Study with Long-Term Follow-up: Untreated HBsAg-positive individuals in Taiwan Acute Infection Chronic Infection 1. Moyer LA, Mast EE. Am J Prev Med. 1994;10(suppl): Perrillo RP et al. Hepatology. 2001;33: % -40% 1 Cirrhosis Liver Failure (Decompensation) Liver Transplant Death 6th leading cause of liver transplantation in the United States 2 Patients (%) Cumulative Incidence of HCC at Year 13 Follow-up 1 (N = 3653) < , ,000 99, Chen CJ, et al. JAMA. 2006;295: Iloeje UH, et al. Gastroenterology. 2006;130: Baseline HBV DNA (copies/ml) Cumulative Incidence of Cirrhosis at Year 13 Follow-up 2 (N = 3582) < ,000-99, ,000-1 million 999,999 HBV IS A SILENT KILLER Chronic HBV infection usually asymptomatic, even with liver cancer and well-compensated cirrhosis Liver panel may be normal As many as 2 out of 3 chronically infected persons are unaware of HBV infection HBV RISK FACTORS FOR PERSONS OF ASIAN AND SUB- SAHARAN DESCENT MYTHS OF HBV TRANSMISSION HBV: MODES OF TRANSMISSION Hepatitis B is not transmitted through: Endemic Countries Non-endemic Countries Casual contact such as hugging or shaking hands Kissing, sneezing, or coughing Breastfeeding Sharing eating utensils or drinking glasses Air/food/water Mother to baby at time of birth (~50% of cases, most common among Asians) Horizontal within household during early childhood (Virus can survive at least 7 days outside body) Health care (Re-use of non-sterilized needles and syringes in resource-poor areas, contaminated blood products) Traditional medicine (Acupuncture, coining, cupping, scarification, etc.) Adult sexual activity (~54% of cases, most common) IV drug use (~20% of cases) Shepard CW, et al. Epidemiol Rev. 2006;28: Stanford Liver Center Hepatitis B FAQs. Accessed March 4, 2011 Shepard, CW et al. Epidemiol Rev. 2006;28: Leung N. Hepatol Int. Dec 2009;3 Suppl 1: WHO Dept. Communicable Diseases Surveillance and Response. Hepatitis B. Accessed March 4,
8 HEPATITIS B SEROLOGY 101 HBsAg: hepatitis B surface antigen Marker of active infection Chronic HBV: HBsAg positive for at least 6 months Anti-HBs (or HBsAb): antibody to HBsAg Marker of immunity to hepatitis B Anti-HB core antibody (IgG) Previous exposure HEPATITIS B SEROLOGY 101 HBeAg: hepatitis B e antigen Surrogate marker of high viral load Anti-HBe: antibody to HBeAg Precore mutation: associated with lower viral load Inactive carrier state HBV DNA: active viral replication Adapted from McMahon, BJ, Peters, M. Accessed March 12, Adapted from McMahon, BJ, Peters, M. Accessed March 12, CLINICAL PROFILES OF CHRONIC HBV INFECTION INTERPRETING SEROLOGIES: MATCHING PATIENTS AND HBV STATUS Marker Patient Populations in Chronic Hepatitis B Immune Tolerant HBeAg+ CHB Inactive HBsAg Carrier HBeAg CHB (Precore Mutant) HBsAg HBeAg + + Anti-HBe + + ALT Normal Normal HBV DNA (copies/ml) > 10 5 > 10 5 < 10 3 > 10 4 Histology Normal/Mild Active Normal Active Korean male, 52 yo HBsAg+, HBeAg-, anti-hbe+ HBV DNA- ALT normal Vietnamese male, 38 yo HBsAg+, HBeAg+, anti-hbe- HBV DNA ALT elevated Nigerian female, 25 yo HBsAg+, HBeAg+, anti-hbe- HBV DNA ALT normal Taiwanese female, 52 yo HBsAg-, anti-hbs-, anti-hbc+ ALT normal Immune active infection Most commonly, resolved infection with waning surface antibody titer Immune tolerant Inactive carrier Lai CL, et al. Lancet. 2003:362: Lok AS, et al. Gastroenterology. 2001;120: WHICH OF THE FOLLOWING IS CORRECT 1. Asian Americans in the United States have lower rates of chronic hepatitis B compared to Asians living in Asia 2. Vertical transmission accounts for at least 50% transmission of hepatitis B infections among Asians. 3. Infection with hepatitis B in infancy results in a 33% risk of developing chronic hepatitis B THE ROLE OF THE PRIMARY CARE PROVIDER (PCP) IN HBV SCREENING, COUNSELING, TREATMENT 4. 1 in 10 Asian Americans are living with chronic hepatitis B 5. Both 2 and 4 5
9 PRESENTATION GOALS THE INSTITUTE OF MEDICINE FINDINGS 2010 Identify factors contributing to the disproportionate burden of cirrhosis and HCC among Asian/Pacific Islanders and Sub-Saharan Africans in US Morbidity and Mortality Related to Hepatitis B Assess system, provider, and patient barriers to HBV screening Lack of Public Awareness Lack of Provider Awareness Develop strategies to overcome these barriers Lack of Public Resource Allocation Adapted from McMahon, BJ, Peters, M. Accessed March 12, POTENTIAL BARRIERS TO SCREENING FOR PHYSICIANS POSSIBLE SOLUTIONS TO BARRIERS FOR PHYSICIANS Primary care visit: too many things to keep track of & accomplish in too short a time Serological results are confusing HBV guidelines are conflicting and/or confusing No reminders built into clinic system (electronic health records, etc.) Use physician extenders to do screening and counseling Use social services for insurance, immigration and care access issues Add HBV risk factor assessment to standard intake forms Use flow sheet to track HBV screening, results and follow-up Programmed alerts in electronic health records POSSIBLE SOLUTIONS TO BARRIERS FOR PATIENTS SYSTEM SOLUTIONS No insurance: Local community health centers provide free screening and vaccination and can refer to appropriate specialist Counseling and education to fight stigma, myths, lack of adherence and follow-up Provide appropriate patient education materials in waiting rooms, examination rooms Work with your physician group, practice, clinic, hospital, etc to make HBV risk assessment and appropriate screening routine part of care 6
10 2008 CDC RECOMMENDATIONS FOR HBV SCREENING Persons born in geographic regions with HBsAg prevalence of 2%: Eastern Europe, Asia, Africa, Middle East, and the Pacific Islands U.S. born persons not vaccinated as infants who parents were born in regions with high HBV endemicity ( 8%) Persons receiving cytotoxic or immunosuppressive therapy Injection drug users Individuals with abnormal liver enzymes of unknown etiology Multiple sex partners Men who have sex with men Weinbaum CM, et al. MMWR Recomm Rep. 2008;57(RR-8):1-20. SCREENING THOSE WHO HAVE BEEN VACCINATED. Some may have been infected with HBV before they received hepatitis B vaccination. Therefore, HBsAg testing is recommended regardless of vaccination history for the following populations: Persons born in geographic regions with HBV prevalence of >2%. US-born persons not vaccinated as infants whose parents were born in regions with high HBV endemicity (>8%) Persons who received hepatitis B vaccination as adolescents or adults after the initiation of risk behaviors Weinbaum CM, et al. MMWR Recomm Rep. 2008;57(RR-8):1-20. INDICATIONS FOR REFERRAL AND WHEN TO TREAT Referral to specialist based on PCP s comfort level Two categories of patients with active disease should be considered for treatment (AASLD guidelines 1 ): Anyone with persistently elevated ALT > 2x ultrasound and elevated HBV DNA 10 5 copies/ml Patients who have active disease monitor regularly with blood work every 3-6 months and liver cancer screening with US q 6 months if meet criteria CASE PRESENTATION 1 Amadu Abbasi 1 Lok AS, et al. Hepatology. 2009;50: * Moderate/severe inflammation or significant fibrosis HOW SHOULD WE EDUCATE THIS PATIENT ON HIS RISK FACTORS AND OBTAIN CONSENT FOR SCREENING WHAT DOES THE FINDING OF AN ISOLATED HB CORE ANTIBODY MEAN 1. Emphasize the role of sexual and injection-drugrelated transmission in HBV acquired outside US 2. Explain HBV is a chronic disease, patients who have it usually have no symptoms for decades 3. Tell him that the CDC recommends screening all Africans 4. 1 & 2 1. False positive 2. Previously exposed to HBV, but surface antigen and/or surface antibody not detectable 3. In the setting of acute hepatitis B infection, immune system is clearing virus, but surface antibody is not detectable yet 4. All of the above 7
11 WHAT FOLLOW-UP TESTS ARE APPROPRIATE FOR A PATIENT WHO HAS A POSITIVE TEST FOR HBV SURFACE ANTIGEN 1. HBeAg and anti-hbeag CASE PRESENTATION 2 Brian Lin 2. HBV DNA 3. Liver function tests 4. All of the above HOW SHOULD PATIENTS IN THE INACTIVE CARRIER PHASE BE MANAGED PATIENTS IN WHICH OF THE FOUR PHASES OF HBV LIFECYCLE SHOULD BE TARGETED FOR TREATMENT 1. Initiate antiviral medications 2. Monitor serology and liver function every 6 months 3. Evaluate with liver biopsy annually 4. Monitor with abdominal CT annually 1. Immune tolerant 2. Immune active/clearance phase 3. Inactive carrier 4. Precore mutant with normal ALT WHICH PHASE OF THE HBV LIFECYCLE IS REFLECTED IN MR. LIN S TEST RESULTS 1. Immune tolerant 2. Immune active/clearance phase 3. Inactive carrier 4. Precore mutant POST-SEMINAR ASSESSMENT 8
12 Please now rate your confidence in correctly identifying a patient s risk for chronic HBV 1. Not Confident 2. Somewhat Confident 3. Neutral 4. Confident 5. Very Confident Please now rate your confidence in treating patients for chronic HBV 1. Not Confident 2. Somewhat Confident 3. Neutral 4. Confident 5. Very Confident PATIENTS IN WHICH OF THE FOUR PHASES OF HBV LIFECYCLE SHOULD BE TARGETED FOR TREATMENT 1. Immune tolerant 2. Immune active/clearance phase 3. Inactive carrier 4. Precore mutant with normal ALT How often will you screen Asian/Asian American patients for chronic HBV 1. Rarely 2. Sometimes 3. Often 4. Always How often will you screen African immigrant patients for chronic HBV 1. Rarely 2. Sometimes 3. Often 4. Always Please now rate your confidence in your ability to interpret hepatitis B screening test results correctly 1. Not Confident 2. Somewhat Confident 3. Neutral 4. Confident 5. Very Confident 9
Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationKaren E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago
Karen E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago 1 2 billion people have been exposed to HBV 350-400 million people chronically
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationHepatitis B: A Silent Epidemic for Asian-Americans
Fiona Hinze HumBio 122M June 6, 2012 Hepatitis B: A Silent Epidemic for Asian-Americans The Issue Hepatitis B is a viral disease that causes 80% of liver cancers (hepatocellular carcinoma). Hepatitis B
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationInternist Diagnosis and Management of Chronic Hepatitis B Virus Infection
UPDATE IN OFFICE MANAGEMENT Internist Diagnosis and Management of Chronic Hepatitis B Virus Infection Brian J. McMahon, MD, a Joan Block, RN, BSN, b Barbara Haber, MD, c Thomas London, MD, d James A. McHugh,
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationCommunity Dialogue Series The Lao Cultural Center. Hepatitis B in Asian Communities
Community Dialogue Series The Lao Cultural Center Hepatitis B in Asian Communities Jian-Min Yuan, MD, PhD Associate Professor Division of Epidemiology and Community Health School of Public Health & The
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationHepatitis B in Africa: Epidemiology, Pathophysiology and Challenges
Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationHow does HBV affect the liver?
Hepatitis B Why is the liver important? Your liver is a vital organ that performs many essential functions. It s the largest solid organ in the body and is located under your rib cage on the upper right
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationMaitines septiembre de 2011 Francisco Jorquera Plaza
Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B Maitines septiembre de 2011 Francisco Jorquera Plaza 2.000 millones de personas infectadas
More informationU.S. Preventive Services Task Force
BONUS DIGITAL CONTENT U.S. Preventive Services Task Force Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Recommendation Statement As published by the U.S. Preventive Services
More informationHepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003
Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationChapter 5 Serology Testing
Chapter 5 Serology Testing 49 50 This page intentionally left blank. Diagnostic Tests for Hepatitis B Virus (HBV) Diagnosis of HBV infection (acute vs. chronic) is based on clinical, laboratory, and epidemiologic
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationNATURAL HISTORY OF HEPATITIS B
NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical
More informationHepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis
Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationOB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program
OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program Dear Colleague, This letter is to introduce myself and explain the role I play with the Alaska Perinatal Hepatitis B Program. Alaska
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationX-Plain Hepatitis B Reference Summary
X-Plain Hepatitis B Reference Summary Introduction Hepatitis B is the most common serious liver infection. It is caused by the hepatitis B virus that attacks the liver. The virus is transmitted through
More informationThe facts you need to know
Hepatitis B The facts you need to know Patient information booklet Know it. Test it. Treat it. Table of contents About this booklet 3 What is hepatitis? 3 What is chronic hepatitis B? 3 Can someone be
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationEpidemiology and Screening for Hepatitis C Infection
Epidemiology and Screening for Hepatitis C Infection Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Epidemiology/Screening for Hepatitis
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationTime to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention
Time to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationHepatitis B at a Glance
Return completed form, preferably within 30 days of U.S. date of arrival, to address on reverse side of this form. Review overseas medical exam if available and document immunization dates. Indicate if
More informationHepatitis B Vaccination and Prevention. Angela M. Jo, MD, MSHS
Hepatitis B Vaccination and Prevention Angela M. Jo, MD, MSHS What is Hepatitis B? A virus that lives in blood and other bodily fluids An infectious disease that causes liver disease and cancer 100 x more
More informationAPPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION. Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College
APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College Mr. Alam is a 32 yr old welder, who has been selected for
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More information26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges
Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids
More informationEpidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur
Epidemiology of Hepatitis B in sub-saharan Africa 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationLifetime risk of infection >60% Early childhood infections common
Hepatitis Community Medicine HBV Public health sig HBV is 100 times more infectious than HIV. >350 million chronically infected worldwide. >1 million people die annually of HBV- related chronic liver disease.
More informationElimination of Perinatal Hepatitis B Transmission
Elimination of Perinatal Hepatitis B Transmission Trudy V. Murphy, MD Division of Viral Hepatitis NCHHSTP, CDC December 19, 2013 Hep B United and WHIAAPI Webinar Background q Hepatitis B is an infection
More informationThe Role of Liver Societies in the Global Viral Hepatitis Response
The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationWhat have we learned from HBV clinical cohorts?
PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationSeroprevalence of Hepatitis B Surface Antigen (HBsAg) Among Patients at a Tertiary Care Hospital in Mumbai, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 4 (2017) pp. 722-726 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.604.088
More informationImproving Access & Linkage to Care in Underserved Populations & Baby Boomers
Improving Access & Linkage to Care in Underserved Populations & Baby Boomers Lesley Miller MD Medical Director, Grady Liver Clinic Associate Professor of Medicine Division of General Medicine and Geriatrics
More informationManagement of Patients with Chronic Hepatitis B: The Alaska Experience
Management of Patients with Chronic Hepatitis B: The Alaska Experience Brian J McMahon, MACP, FAASLD Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Disclosures I have no conflicts
More informationEpidemiology of hepatitis B and D in Greece
Epidemiology of hepatitis B and D in Greece George V. Papatheodoridis Assistant Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationRisk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화
Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationJose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas
Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence
More informationHepatitis B Foundation Annual Progress Report: 2010 Formula Grant
Hepatitis B Foundation Annual Progress Report: 2010 Formula Grant Reporting Period July 1, 2011 December 31, 2011 Formula Grant Overview The Hepatitis B Foundation received $ 895 in formula funds for the
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationThe Role of Liver Societies in the Global Viral Hepatitis Response
The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationHepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD
Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD Director, Program for Viral Hepatitis Elimination, Task Force for Global Health Senior Scientist, National Center for HIV/AIDS,
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationCommunity-Based Services to Improve Hepatitis B Testing and Linkage to Care Among Hard-to-Reach Populations
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division name here Community-Based Services to Improve Hepatitis B Testing and Linkage to Care Among Hard-to-Reach Populations Aaron
More informationPrevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD
Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Hello, my name is Milena Gould Suarez, and today I will present "Prevent Hepatocellular
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationHEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium
HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Anchorage, Alaska USA Goals of My Lecture Highlight the
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationArm yourself against Hep B! Vaccinate
Arm yourself against Hep B! Vaccinate Arm yourself against Hep B! Vaccinate Written by Injecting Drug Users for Injecting Drug Users Why it s important for injecting drug users to know about and understand
More informationHCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis
HCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis Wari Allison MD, PhD Assistant Professor/Research Dept. of Medicine/Infectious Disease Medical Director
More informationPHILLY HEPATITIS ANSWERS ABOUT HEPATITIS
PHILLY HEPATITIS ANSWERS ABOUT HEPATITIS TABLE OF CONTENTS WHAT IS HEPATITIS B? 2 HOW DO PEOPLE GET INFECTED WITH HEPATITIS B? 4 HOW DOES HEPATITIS B AFFECT MY BODY? 6 DOES HEPATITIS B AFFECT PREGNANCY?
More informationLab Underwriting Puzzler. Presented by: Bill Rooney, M.D.
Lab Underwriting Puzzler Presented by: Bill Rooney, M.D. Obtaining Best Results from this presentation For best results please do the following: Select Slide Show from the menu option on top Select From
More information